JNJ Traded 24% Below Estimated Future Cash Flow Value: Is It Undervalued?
Johnson & Johnson (JNJ) has been on a roll, with its stock price increasing by 58.10% over the past year.
The latest development is the U.S. Food and Drug Administration's approval of IMAAVY for warm autoimmune hemolytic anemia.
This news comes after a Louisiana jury verdict in a talc-related mesothelioma case, which has been weighing on investors' minds.
Despite this, Johnson & Johnson's stock price continues to rise, with a 30-day share price return of 8.18% and a 90-day share price return of 20.62%.
Analysts have given the company a consensus price target of $270.59 based on their expectations of future earnings growth, profit margins, and other risk factors.
However, our DCF model suggests that Johnson & Johnson trades about 24.4% below an estimated future cash flow value of $364.27.